Thyroid storm is the state in which increased thyroid hormone levels reach critical levels. Plasma exchange (PE), which reduces circulating thyroid hormone levels, has been used as a treatment option for thyroid storm \[[@CIT0001]\]. While thionamides take a relatively long time to suppress thyroid hormone synthesis, PE rapidly reduces plasma thyroid hormone levels, making it a theoretically useful therapy for patients with thyroid storm. However, to date, there have been only a few studies assessing the effect of PE, with varying results \[[@CIT0002]\]. One reason could be that these previous studies assessed the effect of PE without consideration of the distribution of thyroid hormones in the extravascular space \[[@CIT0005]\]. When the effect of thyroid hormone distribution in the extravascular space is taken into account, whole-body changes in thyroid hormone content during PE cannot be accurately assessed. Thus, in this study, we investigated the therapeutic effects of PE with consideration of thyroid hormone levels in the extravascular space by measuring the changes in thyroid hormone, thyroid-binding globulin (TBG), anti-thyrotropin receptor antibody (TRAb) in plasma, amount of fresh frozen plasma (FFP) required, and volume of waste fluid produced during PE.

1. Patient and Methods {#s1}
======================

A. Clinical Course of a Patient With Graves Disease {#s2}
---------------------------------------------------

A 51-year-old woman with a 5-year history of Graves disease was being treated with methimazole. During hospitalization for a left femoral trochanteric fracture at another hospital, she developed asymptomatic agranulocytosis (white blood cell count 1,100/μL; neutrophil count 286/μL). Methimazole was discontinued and inorganic iodine therapy was initiated. During rehabilitation 3 months after surgery for the fracture, she remained euthyroid with a small dose of inorganic iodine. She was scheduled for radical treatment for Graves disease after rehabilitation for the fracture. However, she suddenly complained of palpitations, diarrhea, and fatigue with elevated fever, which were suspected to be manifestations of thyrotoxicosis. Thus, she was transferred to our hospital for further treatment. Her height was 146.9 cm and her weight was 34.5 kg. She had a large goiter (estimated thyroid volume measured by ultrasonography was 104.1 cm^3^). She had sinus tachycardia (heart rate 110/minute), high fever (38.0°C), and complained of diarrhea. Laboratory data showed thyrotoxicosis (thyrotropin \<0.01 μIU/L; free triiodothyronine \[free T~3~\] \>32.6 pg/mL; free thyroxine \[free T~4~\], \>7.8 ng/dL), positive thyroid autoantibodies (thyroid peroxidase antibodies \>600 IU/mL; thyroglobulin antibodies 526 IU/mL), and presence of TRAb (104.8 IU/L; [Table 1](#T1){ref-type="table"}). Imaging studies did not suggest the presence of heart failure. In accordance with Japan Thyroid Association criteria \[[@CIT0006]\], thyroid storm was suspected. Thus, hydrocortisone (400 mg/day), potassium iodine (200 mg/day), and landiolol as needed were initiated ([Fig. 1](#F1){ref-type="fig"}). On hospital day 4, based on our judgment that the treatment effect was inadequate, we increased the dosage of potassium iodine, replaced the short-acting steroid with a longer-acting steroid to more effectively block the conversion of T~4~ to T~3~, and added lithium carbonate (600 mg/day) to suppress hormone secretion. However, the patient responded poorly to treatment that would allow for surgery to be performed safely, so we decided to perform PE before surgery based on 2016 American Thyroid Association guidelines \[[@CIT0007]\].

###### 

Blood Testing Results

  CBC                                      Reference                                          Reference
  --------------------- ------ ----------- ------------ ------------------- -------- -------- -----------
  WBC count             3200   /μL         3600--8900   Uric acid           6.9      mg/dL    2.3--6.0
  Neutrophil            57.4   \%          2--90        Total cholesterol   79       mg/dL    150--219
   Lymphocyte           34.8   \%          25--48       Triglyceride        69       mg/dL    30--149
  Monocyte              7.2    \%          2--12        LDL cholesterol     32       mg/dL    70--139
  Eosinophil            0.3    \%          1--9         Sodium              141      mmol/L   135--145
  Basophil              0.3    \%          0--2         Potassium           3.3      mmol/L   3.5--5.0
  RBC count             416    ×10^4^/μL   380--504     Chloride            104      mmol/L   96--107
  Hemoglobin            11.1   g/dL        11.1--15.2   Calcium             9.0      mg/dL    8.8--10.6
  Platelet count        20.2   ×10^4^/μL   15.3--34.6   Phosphate           4.5      mg/dL    2.4--4.5
  **Chemical**                                          BNP                 151.2    pg/mL    0.0--18.4
  ALP                   302    U/L         110--348     CRP                 0.12     ng/mL    \<0.30
  AST                   36     U/L         5--37        **Thyroid**                           
  ALT                   43     U/L         6--43        TSH                 \<0.01   μIU/mL   0.56--4.3
  LDH                   203    U/L         119--221     Free T~3~           \>32.6   pg/mL    2.4--4.5
  Creatine kinase       47     U/L         47--200      Free T~4~           \>7.8    ng/dL    1.0--1.7
  Total protein         5.8    g/dl        6.5--8.5     TRAb                104.8    IU/L     \<2.0
  Albumin               3.1    g/dl        4.0--5.2     TPOAb               \>600    IU/mL    \<16
  Blood urea nitrogen   23     mg/dl       9--21        TgAb                526      IU/mL    \<28
  Creatinine            0.29   mg/dl       0.50--0.80   Thyroglobulin       1060     ng/mL    \<33.6

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, brain-type natriuretic peptide; CRP, C-reactive protein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; RBC, red blood cell; TSH, thyroid-stimulating hormone; T~3~, triiodothyronine; T^4^, thyroxine; TgAb, thyroglobulin antibody; TPOAb, thyroid peroxidase antibody; TRAb, anti-thyrotropin receptor antibody; WBC, white blood cell.

![Clinical Course of Thyrotoxicosis. Plasma exchange was performed on hospital days 11 and 14. Surgery was performed on hospital day 19. The over-limit data of free triiodothyronine (\[T3\] \>32.6 pg/mL) on day 0 (admission) and free thyroxine (\[T4\] \>7.8 pg/mL) from day 0 to day 11 (at the beginning of plasma exchange \[PE\]) were assigned as upper-limit values. Landiolol 1γ = 1 μg/kg/min. Abbreviations: TRAb, thyrotropin receptor antibody; y, year.](bvaa023f0001){#F1}

B. Plasma Exchange {#s3}
------------------

The patient underwent 2 PE procedures. Each PE procedure entailed exchanges of approximately 2900 mL of FFP as replacement solution over approximately 2.5 hours. Both procedures involved single-filtration PE using nafamostat mesylate for anticoagulation and a blood access catheter kit for vascular access.

C. Specimen Sampling {#s4}
--------------------

We took blood samples at the beginning of PE, 10, 15, 30, 60, 90, 120, and 150 minutes after the start of PE and at the end of PE. We also took a sample from each bag of FFP (Japan Red Cross Society) and a sample of a part of total waste plasma. For all specimens, we measured T~3~ and T~4~ concentrations and TRAb titers. We used a commercial electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics, Tokyo) to measure total T~3~ and T~4~ concentrations (normal range for T~4~: 6.18--12.40 μg/dL; for T~3~: 0.80--1.60 ng/mL). We used the ECLusys TRAb 2-step radioreceptor assay (Roche Diagnostics) to measure TRAb titers (normal range \<2.0 IU/L; detectable level ≥0.3 IU/L). We also measured serum free T~4~ and free T~3~ concentrations using ECLIA (Roche Diagnostics) to assess the patient's clinical condition. (For these assays, the reference range is 1.00--1.70 ng/dL for free T~4~ and 2.40--4.50 pg/mL for free T~3~.)

D. Estimation of Whole-Body Plasma Volume {#s5}
-----------------------------------------

In this study, we used Gibson's formula \[[@CIT0008], [@CIT0009]\] to calculate circulating plasma volume (PV) by multiplying average circulating plasma volume per area of body surface for this patient (2715 mL/m^2^) by hematocrit, as follows:

W

h

o

l

e

\-

b

o

d

y

p

l

a

s

m

a

v

o

l

u

m

e

(

P

V

)

=

2715

×

\[

h

e

i

g

h

t

(

1

.

469

m

)

0\.

725

×

b

o

d

y

w

e

i

g

h

t

(

k

g

)

0\.

425

×

0.00

7184

\]

×

(

1

−

h

e

m

a

t

o

c

r

i

t

\[

\%

\]

/

1

00

)

E. Calculation of Amount of Thyroid Hormone {#s6}
-------------------------------------------

We calculated thyroid hormone balance during PE with an assumption of equality as follows:
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Using this equation, the change in thyroid hormone content in the extravascular space was calculated as follows:
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2. Results {#s7}
==========

For the first PE procedure, the estimated PV was 1.54 L before the procedure and 1.57 L after the procedure. For the second PE procedure, the values were 1.48 L and 1.50 L, respectively. The difference between PV before and after PE was small (0.02--0.03 L). [Figure 2](#F2){ref-type="fig"} shows the changes in estimated plasma thyroid hormone content during PE. During the first PE procedure, plasma content of both T~4~ and T~3~ continuously decreased until 120 minutes after the beginning of PE. An absolute reduction in plasma T~3~ and T~4~ content was observed at the end of PE. The second PE procedure took place 3 days after the first PE procedure. Plasma thyroid hormone content at the beginning of the second PE procedure was much lower than content at the end of the first PE procedure. During the second PE procedure, decreases in plasma T~4~ and T~3~ content were not observed. T~3~ and T~4~ content were higher at the end of the second PE procedure despite a constant PE speed. These data suggest that the reduction in plasma thyroid hormones was not consistent during PE. Accordingly, we estimated the balance of T~4~, TBG, and TRAb levels during PE using assumptions of equality.

![Changes in Plasma Triiodothyronine and Thyroxine Content During Plasma Exchange (PE). Estimated plasma triiodothyronine (T~3~) and thyroxine (T~4~) content over time during the first and second PE procedures. The interval between the first and second PE procedures was 3 days. Abbreviations: BW, body weight; Htc, hematocrit.](bvaa023f0002){#F2}

[Table 2](#T2){ref-type="table"} shows the content and estimated balance of T~4~ and TBG during each PE procedure. For the first PE procedure, the estimated plasma content of T~4~ was 644 μg and 426 μg before and after PE, respectively. T~4~ content was 89 μg in total FFP and 337 μg in waste fluid. The estimated balance in the extravascular space (ΔX) was −70 μg, approximately 18.6% of T~4~ content in the waste fluid. For the second PE procedure, ΔX was −131 μg, approximately 51.8% of T~4~ content in the waste fluid. Faber et al found the rate of T~4~ turnover was 36.7 nmol (28.5 μg)/day \[[@CIT0010]\]. When corrected by PE duration (approximately 2.5 hours), the rate of T~4~ turnover was assumed to be 3.0 μg. When the rate of T~4~ turnover was taken into account, net ΔX for T~4~ was −67 μg for the first PE procedure and −128 μg for the second PE procedure, which indicates that the movement of T~4~ into waste fluid was much higher than T~4~ turnover in plasma. T~4~ movement into the extravascular space is a considerable contributor to T~4~ removal during PE, and the distribution of T~4~ sources during PE was not constant.

###### 

Estimated Thyroxine and Thyroid-Binding Globulin Content in Plasma at the Beginning and End of Plasma Exchange, Total Fresh Frozen Plasma, and Waste Fluid

  Parameter   PE procedure   Before PE   After PE   FFP    Waste fluid   ΔX
  ----------- -------------- ----------- ---------- ------ ------------- -------
  T~4~ (μg)   1              644         426        89     377           −70
              2              342         312        92     253           −131
  TBG (mg)    1              48.6        54.0       27.6   40.0          −17.8
              2              55.7        61.4       29.7   49.0          −25.0

FFP, fresh frozen plasma; PE, plasma exchange; T~4~, thyroxine; TBG, thyroid-binding globulin; ΔX, estimated balance in the extravascular space.

Of note, the estimated balance of TBG (ΔX) was −17.8 mg for the first PE procedure and −25.0 mg for the second PE procedure ([Table 2](#T2){ref-type="table"}). The estimated balance of plasma TRAb was −97 IU and −64 IU for the first and second PE procedures, respectively ([Table 3](#T3){ref-type="table"}).

###### 

Estimated Thyrotropin Receptor Antibody Titers in Plasma at the Beginning and End of Plasma Exchange, Total Fresh Frozen Plasma, and waste Fluid

  Parameter   PE procedure   Before PE   After PE   FFP   Waste fluid   ΔP
  ----------- -------------- ----------- ---------- ----- ------------- ------
  TRAb (IU)   1              310         77         0     97            -233
              2              111         42         0     64            -69

FFP, fresh frozen plasma; PE, plasma exchange; ΔP, estimated balance in the plasma; TRAb, thyrotropin receptor antibody.

At 1 day and 3 days after the first PE procedure, plasma free T~4~ levels were 3.6 and 2.9 ng/dL, respectively ([Fig. 1](#F1){ref-type="fig"}). Five days after the second PE procedure, the patient successfully underwent total thyroidectomy. The pathological features of the resected thyroid were consistent with Graves disease. Overall, PE seemed to be effective in improving her condition.

3. Discussion {#s8}
=============

This is the first report to assess the effect of PE in patients with thyroid storm that takes whole-body balance of T~4~ during PE into consideration. Here, we showed that PE was effective for removing T~4~ in this patient, although the proportion of T~4~ removed from various origins during PE was not constant.

Previous studies evaluating the effect of PE have demonstrated absolute changes in plasma thyroid hormone levels during PE. However, they concluded that a remarkable effect was not observed \[[@CIT0002]\]. Those studies did not consider thyroid hormone content in the extravascular space. Indeed, the extravascular space is considered another location for T~4~ and TBG \[[@CIT0005]\]. To investigate the kinetics of T~4~, Irvine and Simpson-Morgan monitored the appearance of T4 labeled with exogenous iodine (^125^I-T~4~) and albumin labeled with iodine 131 (^131^I-albumin) over time, which bind to T~4~ from central venous catheters in the hepatic, intestinal, and popliteal lymph ducts in sheep \[[@CIT0011]\]. They found that exogenous ^125^I-T~4~ and ^131^I-albumin in the vascular space flow into lymph ducts, and their distribution between the vascular and extravascular spaces (lymph ducts) reached an equilibrium. In addition, Fisher et al investigated the peripheral kinetics of T~4~ labeled with iodine 131 (131I-T~4~) in healthy adults and patients with thyrotoxicosis using a four-compartment mathematical model \[[@CIT0012]\]. They found that total T~4~ distribution in plasma, liver, and extravascular space (lymph ducts and interstitial tissue) is more extensive in patients with thyrotoxicosis than in healthy adults. Accordingly, our calculations for assessing the effect of PE seem reasonable.

Regarding the relationship between changes in plasma and extravascular space T~4~ content, a large amount of T~4~ wasting from plasma was accompanied by a small amount of T~4~ wasting from the extravascular space during the first PE procedure, which might reflect a large reduction in plasma T~4~ levels. Conversely, a small amount of T~4~ wasting from plasma was accompanied by a large amount of T~4~ wasting from the extravascular space during the second PE procedure, which might reflect a small reduction in the plasma T~4~ (or free T~4~) levels. We are not aware of the factors regulating the wasting fractions in each PE.

This study had several limitations. First, estimations of circulating PV and turnover rate were based on assumption of equality as in previous studies. Second, this case report is based on a single patient. We need further investigations involving patients with Graves disease who undergo PE to elucidate its true therapeutic effects.

In conclusion, we demonstrated that PE is effective for removing thyroid hormones. The true therapeutic effects of PE might have been misinterpreted when only changes in plasma concentrations of thyroid hormones were taken into account.

The authors thank Takuya Nemoto for excellent technical assistance.

FFP

:   fresh frozen plasma

PE

:   plasma exchange

PV

:   plasma volume

T3

:   triiodothyronine

T4

:   thyroxine

TBG

:   thyroid-binding globulin

TRAb

:   thyrotropin receptor antibody

ΔX

:   balance in the extravascular space

Additional Information {#s0100}
======================
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